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Objective 
 
This study was primarily designed to 
evaluate two hypotheses:   
 
1. For those women with mild 
preeclampsia, ceasing 
magnesium sulfate therapy 
after diuresis (see above for 
criteria) does not increase the 
risk of having to re-start 
magnesium sulfate therapy. 
   
2. For those women with severe 
preeclampsia, using the 
above diuresis criteria to allow 
cessation of magnesium 
sulfate prior to 24 hours post-
delivery would not put them at 
any increased risk of having 
to re-start magnesium sulfate 
therapy. 
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Background 
 
Preeclampsia is a multisystem 
disorder that complicates 
approximately 5-8% of pregnancies.  
Although outcomes are generally 
good, preeclampsia is a major cause 
of morbidity and mortality for a 
woman and her unborn child.  
Preeclampsia and eclampsia 
probably account for more than 
50,000 maternal deaths a year.   
 
The use of magnesium sulfate for 
seizure prophylaxis in women with 
preeclampsia was well established 
by the Magpie Trial in 2002.1   
 
It is known that the clinical 
manifestations of preeclampsia are a 
result of widespread 
vasoconstriction.  It is therefore 
thought that the onset of diuresis 
may signal a reversal of this 
vasoconstriction, and thus resolution 
of the disease.  Here at the 
University of Iowa Hospitals and 
Clinics (UIHC), women with mild 
preeclampsia are treated with post-
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partum magnesium sulfate until 
specific diuresis criteria are met (200 
ml urine/hour for four consecutive 
hours) or for a maximum of 24 hours 
post-delivery.  Women with severe 
preeclampsia are routinely given 24 
hours of magnesium sulfate therapy 
post-delivery regardless of urine 
output. 
 
Methods 
 
This retrospective cohort study was 
conducted at the University of Iowa 
Hospitals and Clinics (UIHC) to 
validate our diuresis criteria and 
determine if there was a trend for 
diuresis that was dependent on the 
type of preeclampsia.  UIHC 
institutional review board approval 
was obtained prior to the study.  
Medical records were selected for 
review based on billing codes for 
hypertension and preeclampsia; we 
report data from patients discharged 
from UIHC between March, 2004 
and May, 2008.  Medical records of 
this cohort of patients were utilized to 
extract pertinent data including 
demographics, medical and 
obstetrical history data, labor 
characteristics, urine outputs during 
magnesium sulfate therapy and 
newborn characteristics.   
 
The use of magnesium sulfate at the 
University of Iowa Hospital and 
Clinics is as follows: Women 
diagnosed with mild preeclampsia 
receive 2 grams of magnesium 
sulfate per hour until diuresis criteria 
are met (see above for details) or 
they reach 24 hours post-delivery at 
which point it is discontinued.  
Women diagnosed with severe 
preeclampsia receive 2 grams of 
magnesium sulfate per hour for 24 
hours post-delivery regardless of 
urine output.  Any decision to restart 
magnesium sulfate was made by the 
resident and attending physician that 
were on Labor and Delivery at that 
time and included patient symptoms 
consistent with preeclampsia as well 
as uncontrolled high blood 
pressures.  Due to the fact that 
eclampsia is a rare event, we used 
the re-initiation of magnesium sulfate 
as our primary outcome. 
 
Results  
 
There were no surprises in terms of 
differences that were significantly 
different including: gestational age at 
delivery, urine dip on admission, 
aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) 
on admission, 24 hour urine protein, 
birth weight and Apgar scores at 1 
and 5 minutes.  The time to diuresis 
was significantly different. 
 
Rates of re-administration of 
magnesium sulfate were compared 
between the patients with mild 
preeclampsia, the patients with 
severe preeclampsia that did not 
diuresis and the patients with severe 
preeclampsia that would have met 
our diuresis criteria.  There is a trend 
toward a significant difference 
between those patients with mild 
preeclampsia and those with severe 
preeclampsia who never met 
diuresis criteria.  There was no 
difference in the rate of re-initiating 
magnesium sulfate when comparing 
those patients with mild 
preeclampsia and those with severe 
preeclampsia who would have met 
diuresis criteria. 
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Conclusion 
 
This study suggests that the diuresis 
curves for those women with mild 
preeclampsia and severe 
preeclampsia do not vary 
significantly after the first 5 hours.  It 
also appears that the rate of re-
initiation of magnesium sulfate is low 
for those women diagnosed with mild 
preeclampsia and treated using the 
UIHC protocol for magnesium sulfate 
administration post-delivery.     
 
We were able to separate the 
women with severe preeclampsia 
into two groups, one of which would 
have met our diuresis criteria prior to 
24 hours and the other of which 
would not have met diuresis criteria 
at 24 hours post-delivery.  It is 
interesting to note that when these 
groups were compared, there is a 
trend toward a significant difference 
between those patients with mild 
preeclampsia and those with severe 
preeclampsia who never met 
diuresis criteria.  It is also interesting 
to note that there was no significant 
difference in the rate of restarting 
magnesium sulfate for women with 
mild preeclampsia and those with 
severe preeclampsia who would 
have met diuresis criteria.  It seems 
reasonable to conclude that it may 
not be necessary to require 24 hours 
of magnesium sulfate for those 
women with severe preeclampsia 
who meet diuresis criteria.   
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